ArticleBlood2022
Genomic profiling for clinical decision making in lymphoid neoplasms.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 2 pooled it
21.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- NKG2D genetic variants and cancer susceptibility: Integrating case-control evidence with meta-analysis.Immunogenetics · 2026Pooled it
- A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2026Article
- AI for prognostic assessment of diffuse large B-cell lymphoma using H&E whole-slide images.HemaSphere · 2026Article
- Article
- Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.Clinical and translational medicine · 2026Article
- Molecular Feasibility of Gene Sequencing on Lymph Node Fine-Needle Cytology Samples of Non-Hodgkin Lymphoma.International journal of molecular sciences · 2026Article
- SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies.International journal of clinical oncology · 2026Article
- Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026Review
- Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.AIDS (London, England) · 2026Article
- Article
- Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.Annals of laboratory medicine · 2026Article
- Integrating Rapid Lymphoma Next-Generation Sequencing Panel-Based Testing into Routine Genomic Diagnostics.Annals of laboratory medicine · 2026Article
- Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.Molecular cancer · 2026Article
- Targeted panel sequencing for refining B-cell lymphoma diagnosis: a real-life, reference center experience.Virchows Archiv : an international journal of pathology · 2026Article
- Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.Blood advances · 2026Article
- Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture.International journal of molecular sciences · 2025Article
- Article
- A rare case of large B-cell lymphoma with IRF4 rearrangement and concomitant 11q aberrations: a diagnostic pitfall in the molecular era.Virchows Archiv : an international journal of pathology · 2025Article
- Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas.Blood advances · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
72 authors at 20 institutions in 13 countries.
Laurence de LevalInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.ORCID 0000-0003-3994-516X
Ash A AlizadehDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA.ORCID 0000-0002-5153-5625
P Leif BergsagelDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ.ORCID 0000-0003-1523-7388
Elias CampoHaematopathology Section, Hospital Clínic, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.ORCID 0000-0001-9850-9793
Andrew DaviesCentre for Cancer Immunology, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-7517-6938
Ahmet DoganDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6576-5256
Jude FitzgibbonHaemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-9069-1866
Steven M HorwitzLymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-6399-2006
Ari M MelnickDepartment of Medicine, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-8074-2287
William G MoriceDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-5801-2501
Ryan D MorinDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.ORCID 0000-0003-2932-7800
Bertrand NadelAix Marseille University, CNRS, INSERM, CIML, Marseille, France.ORCID 0000-0002-4644-5617
Stefano A PileriHaematopathology Division, IRCCS, Istituto Europeo di Oncologia, IEO, Milan, Italy.ORCID 0000-0001-8032-5128
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-0211-8788
Davide RossiInstitute of Oncology Research and Oncology Institute of Southern Switzerland, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland.
Itziar SalaverriaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0002-2427-9822
Christian SteidlCentre for Lymphoid Cancer, BC Cancer and University of British Columbia, Vancouver, Canada.ORCID 0000-0001-9842-9750
Steven P TreonDana Farber Cancer Institute, Boston, MA.ORCID 0000-0001-6393-6154
Andrew D ZelenetzLymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-1403-6883
Ranjana H AdvaniDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA.
Carl E AllenDivision of Pediatric Hematology-Oncology, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-6625-739X
Stephen M AnsellMayo Clinic Cancer Center, Rochester, MN.ORCID 0000-0003-1244-6758
Wing C ChanDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-6243-6008
James R CookPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-0456-8085
Lucy B CookCentre for Haematology, Imperial College London, London, United Kingdom.ORCID 0000-0002-8234-5090
Francesco d'AmoreDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-4032-6633
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Martin DreylingDepartment of Medicine III, LMU Hospital, Munich, Germany.ORCID 0000-0002-0358-5249
Kieron DunleavyDivision of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Centre, Georgetown University Hospital, Washington, DC.ORCID 0000-0003-1985-8296
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5009-4808
Falko FendInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-5496-293X
Philippe GaulardDepartment of Pathology, University Hospital Henri Mondor, AP-HP, Créteil, France.ORCID 0000-0002-4243-905X
Paolo GhiaUniversità Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0003-3750-7342
John G GribbenHaemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-8505-7430
Olivier HermineService D'hématologie, Hôpital Universitaire Necker, Université René Descartes, Assistance Publique Hôpitaux de Paris, Paris, France.ORCID 0000-0003-2574-3874
Daniel J HodsonWellcome MRC Cambridge Stem Cell Institute, Cambridge Biomedical Campus, Cambridge, United Kingdom.ORCID 0000-0001-6225-2033
Eric D HsiDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC.ORCID 0000-0001-8623-4067
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.ORCID 0000-0001-5566-0864
Elaine S JaffeHematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-4632-0301
Kennosuke KarubeDepartment of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-1205-858X
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Toyko, Japan.ORCID 0000-0002-8263-9902
Wolfram KlapperHematopathology Section and Lymph Node Registry, Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany.ORCID 0000-0001-7208-4117
Won Seog KimSungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Rebecca L KingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-7132-0226
Young H KoDepartment of Pathology, Cheju Halla General Hospital, Jeju, Korea.ORCID 0000-0002-4383-0579
Ann S LaCasceDana Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7349-0176
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.ORCID 0000-0002-4728-1693
José I Martin-SuberoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Miguel A PirisDepartment of Pathology, Jiménez Díaz Foundation University Hospital, CIBERONC, Madrid, Spain.ORCID 0000-0001-5839-3634
Stefania PittalugaHematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7688-1439
Laura PasqualucciInstitute for Cancer Genetics, Columbia University, New York, NY.ORCID 0000-0001-6819-7370
Leticia Quintanilla-MartinezInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0001-7156-5365
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.ORCID 0000-0003-1761-9769
Andreas RosenwaldDepartment of Pathology, University of Würzburg, Würzburg, Germany.ORCID 0000-0001-7282-8374
Gilles A SallesLymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9541-8666
Jesus San-MiguelClínica Universidad de Navarra, Navarra, Cancer Center of University of Navarra, Cima Universidad de NavarraI, Instituto de Investigacion Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Céncer, Pamplona, Spain.ORCID 0000-0002-9183-4857
Kerry J SavageCentre for Lymphoid Cancer, BC Cancer and University of British Columbia, Vancouver, Canada.ORCID 0000-0002-5835-9863
Laurie H SehnCentre for Lymphoid Cancer, BC Cancer and University of British Columbia, Vancouver, Canada.ORCID 0000-0003-1860-9765
Gianpietro SemenzatoDepartment of Medicine, University of Padua and Veneto Institute of Molecular Medicine, Padova, Italy.ORCID 0000-0002-6061-4595
Louis M StaudtLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-1735-2892
Steven H SwerdlowDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA.ORCID 0000-0002-3832-3329
Constantine S TamAlfred Hospital and Monash University, Melbourne, Australia.ORCID 0000-0002-9759-5017
Judith TrotmanHaematology Department, Concord Repatriation General Hospital, Sydney, Australia.ORCID 0000-0001-8009-4593
Julie M VoseDepartment of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-1015-7434
Oliver WeigertDepartment of Medicine III, LMU Hospital, Munich, Germany.ORCID 0000-0002-0987-7373
Wyndham H WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-2862-9711
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL.ORCID 0000-0001-7542-3305
Catherine J WuDana Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3348-5054
Pier L ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna Istitudo di Ematologia "Seràgnoli" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy.ORCID 0000-0002-2112-2651
Emanuele ZuccaInstitute of Oncology Research and Oncology Institute of Southern Switzerland, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona, Switzerland.ORCID 0000-0002-5522-6109
Adam BaggDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-1669-468X
David W ScottCentre for Lymphoid Cancer, BC Cancer and University of British Columbia, Vancouver, Canada.ORCID 0000-0002-0435-5947
Memorial Sloan Kettering Cancer Center · USNational Institutes of Health · USUniversity of British Columbia · CADana-Farber Cancer Institute · USMayo Clinic in Arizona · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESCornell University · USInstitute of Oncology Research · CHIstituti di Ricovero e Cura a Carattere Scientifico · ITLMU Klinikum · DEQueen Mary University of London · GBUniversity of Tübingen · DEAarhus University Hospital · DKBaylor College of Medicine · USBrigham and Women's Hospital · USCalifornia Institute for Regenerative Medicine · USCentre National de la Recherche Scientifique · FRCheju Halla General Hospital · KRCity Of Hope National Medical Center · USCleveland Clinic · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0MThe PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3MCancer Research UK 26819NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA154947NICHD NIH HHS R33 HD105593
Abstract
With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.
Indexed as
LymphomaNeoplasmsClinical Decision-MakingGenomicsHigh-Throughput Nucleotide SequencingHumansPrecision Medicine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.